Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

被引:338
作者
Robinson, HL [1 ]
Montefiori, DC
Johnson, RP
Manson, KH
Kalish, ML
Lifson, JD
Rizvi, TA
Lu, S
Hu, SL
Mazzara, GP
Panicali, DL
Herndon, JG
Glickman, R
Candido, MA
Lydy, SL
Wyand, MS
McClure, HM
机构
[1] Yerkes Reg Primate Res Ctr, Atlanta, GA 30329 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] New England Reg Primate Res Ctr, Southborough, MA 01772 USA
[4] Harvard Univ, Sch Med, AIDS Res Ctr, Southborough, MA 01772 USA
[5] GTC Mason Labs, Worcester, MA 01608 USA
[6] Ctr Dis Control, Atlanta, GA 30333 USA
[7] NCI, Frederick Canc Res Ctr, Frederick, MD 21702 USA
[8] Univ Texas, MD Anderson Canc Ctr, Bastrop, TX 78802 USA
[9] Univ Massachusetts, Med Ctr, Div Infect Dis, Worcester, MA 01655 USA
[10] Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA
[11] Therion Biol, Cambridge, MA 02142 USA
关键词
D O I
10.1038/8406
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eight different protocols were compared for their ability to raise protection against immunodeficiency virus challenges in rhesus macaques. The most promising containment of challenge infections was achieved by intradermal DNA priming followed by recombinant fowl pox virus booster immunizations. This containment did not require neutralizing antibody and was active for a series of challenges ending with a highly virulent virus with a primary isolate envelope heterologous to the immunizing strain.
引用
收藏
页码:526 / 534
页数:9
相关论文
共 49 条
[1]  
ANDERSSON S, 1989, J BIOL CHEM, V264, P8222
[2]   PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES [J].
BABA, TW ;
JEONG, YS ;
PENNINCK, D ;
BRONSON, R ;
GREENE, MF ;
RUPRECHT, RM .
SCIENCE, 1995, 267 (5205) :1820-1825
[3]   Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [J].
Boyer, JD ;
Ugen, KE ;
Wang, B ;
Agadjanyan, M ;
Gilbert, L ;
Bagarazzi, ML ;
Chattergoon, M ;
Frost, P ;
Javadian, A ;
Williams, WV ;
Refaeli, Y ;
Ciccarelli, RB ;
McCallus, D ;
Coney, L ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (05) :526-532
[4]   Why do we not have an HIV vaccine and how can we make one? [J].
Burton, DR ;
Moore, JP .
NATURE MEDICINE, 1998, 4 (05) :495-498
[5]   Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [J].
Connor, RI ;
Korber, BTM ;
Graham, BS ;
Hahn, BH ;
Ho, DD ;
Walker, BD ;
Neumann, AU ;
Vermund, SH ;
Mestecky, J ;
Jackson, S ;
Fenamore, E ;
Cao, Y ;
Gao, F ;
Kalams, S ;
Kunstman, KJ ;
McDonald, D ;
McWilliams, N ;
Trkola, A ;
Moore, JP ;
Wolinsky, SM .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1552-1576
[6]   PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE [J].
DANIEL, MD ;
KIRCHHOFF, F ;
CZAJAK, SC ;
SEHGAL, PK ;
DESROSIERS, RC .
SCIENCE, 1992, 258 (5090) :1938-1941
[7]   Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection [J].
Dittmer, U ;
Brooks, DM ;
Hasenkrug, KJ .
NATURE MEDICINE, 1999, 5 (02) :189-193
[8]   DNA vaccines [J].
Donnelly, JJ ;
Ulmer, JB ;
Shiver, JW ;
Liu, MA .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :617-648
[9]   NATIVE OLIGOMERIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN ELICITS DIVERSE MONOCLONAL-ANTIBODY REACTIVITIES [J].
EARL, PL ;
BRODER, CC ;
LONG, D ;
LEE, SA ;
PETERSON, J ;
CHAKRABARTI, S ;
DOMS, RW ;
MOSS, B .
JOURNAL OF VIROLOGY, 1994, 68 (05) :3015-3026
[10]  
Feltquate DM, 1997, J IMMUNOL, V158, P2278